Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project
-
Published:2023-05-05
Issue:11
Volume:149
Page:8829-8842
-
ISSN:0171-5216
-
Container-title:Journal of Cancer Research and Clinical Oncology
-
language:en
-
Short-container-title:J Cancer Res Clin Oncol
Author:
Braulke Friederike, Para Servet, Alt-Epping Bernd, Tewes Mitra, Bäumer Markus, Haberland Birgit, Mayer-Steinacker Regine, Hopprich Anne, de Wit Maike, Grabe Michaela, Bender-Säbelkampf Sophia, Weßling Caroline, Aulmann Christoph, Gerlach Christina, Regincos Pascale, Fischer Ferdinand, Haarmann Soraya, Huys Tatjana, Drygas Sabine, Rambau Anett, Kiani Alexander, Schnabel Astrid, Buhl Christoph, Seipke Stefanie, Hiemer Sonja, Polata Silke, Meßmann Maximilian, Hansmeier Anna, Anastasiadou Louiza, Letsch Anne, Wecht Daniel, Hellberg-Naegele Matthias, Krug Utz, Wedding UlrichORCID, van Oorschot Birgitt
Abstract
Abstract
Purpose
Guidelines recommend a structured symptom screening (SC) for especially advanced cancer patients (CPs). The aim of this multicenter German prospective quality assurance project KeSBa (Kennzahl Symptom- und Belastungserfassung) was to gain knowledge on SC procedures in Oncology Centers (OCs) for advanced cancer patients and a first impression on the consequences of SC.
Methods
The KeSBa project consisted of three phases: pilot, 3 months screening and feedback phase. Participating OCs decided to use either the Minimal Documentation System (MIDOS) or the Integrated Palliative care Outcome Scale (IPOS) and defined the cutoff values for positive screening results.
Results
Out of 172 certified German OCs, 40 (23%) participated in the KeSBa pilot phase, 29 (16.8%) in the 3 months screening phase using MIDOS (n = 18, 58.6%) or IPOS (n = 11, 41.3%) and in the feedback round. 25/29 performed paper-based screening (86.2%). 2.963 CPs were screened. Results were documented for 1255 (42.2%, SC +) positive and 874 (29.5%, SC–) negative screenings depending on the center´s schedules: 452 SC + CPs (28.4%) and 42 SC– CPs (2.6%) had contact to specialized palliative care or other supportive specialist teams afterwards, 458 SC + CPs (28.8%) and 605 SC– CPs (38.1%) remained in standard oncology care. In the feedback round missing resources (personal and IT) and improved communication were mentioned most often.
Conclusion
Routine SC is feasible in advanced CPs treated in OCs but associated with considerable workload. In 42.2% of CPs SC was classified as positive, indicating the need of further diagnostics or professional judgment. SC requires staff and IT resources.
Funder
Friedrich-Schiller-Universität Jena
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference46 articles.
1. Barbera L, Seow H, Howell D, Sutradhar R, Earle C, Liu Y, Stitt A, Husain A, Sussman J, Dudgeon D (2010) Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116(24):5767–5776. https://doi.org/10.1002/cncr.25681. (Epub 2010 Nov 8 PMID: 21136579) 2. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. https://doi.org/10.1200/JCO.2015.63.0830 3. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O’Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D (2017) Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials. JAMA Oncol 3(8):1043–1050. https://doi.org/10.1001/jamaoncol.2016.6749.PMID:28208174;PMCID:PMC5553624 4. Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC (2022) Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA 327(24):2413–2422. https://doi.org/10.1001/jama.2022.9265.PMID:35661856;PMCID:PMC9168923 5. Book K, Marten-Mittag B, Henrich G, Dinkel A, Scheddel P, Sehlen S, Haimerl W, Schulte T, Britzelmeir I, Herschbach P (2011) Distress screening in oncology-evaluation of the questionnaire on distress in cancer patients-short form (QSC-R10) in a German sample. Psychooncology 20(3):287–293. https://doi.org/10.1002/pon.1821. (PMID: 20669340)
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|